BioSpace News Archive

Drug Development

AstraZeneca’s Calquence Fails Pair of Phase II COVID-19 Trials

AstraZeneca reported that the CALAVI Phase II trials of Calquence (acalabrutinib) in hospitalized patients with respiratory symptoms of COVID-19 failed to meet the trials’ primary efficacy endpoint.

November 12, 2020
·
3 min read
·
Mark Terry
Biotech Bay

New Animal Data Shows Promise for Vaxart’s Oral COVID-19 Vaccine

Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a significant immune response.

November 12, 2020
·
3 min read
·
Krystle Vermes
Career Advice

Should You Change Careers During a Pandemic?

If you’re contemplating changing careers in the midst of the COVID-19 pandemic, the reality is that if it’s time to make a change, there’s no time like the present.

November 12, 2020
·
3 min read
·
Kymberlie Krieger
Business

Blast Off! Two Companies Launch with Millions in Financing to Develop New Therapies

Two new companies exploded onto the scene this morning, backed by significant financing that will be used to develop treatments for a wide range of diseases.

November 12, 2020
·
4 min read
·
Alex Keown
Drug Development

NECI’s Digital Stack Helps Moderna Create its COVID-19 Vaccine in Record Time

Integrating digital tools for manufacturing process development, control and data analytics brings data together in ways that enhance visibility system-wide.

November 12, 2020
·
4 min read
·
Gail Dutton
Research Roundup: COVID-19 and Psychiatric Disorders and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

November 12, 2020
·
5 min read
·
Mark Terry
Deals

UCB Flexes M&A Muscles to Bolster its Gene Therapy Capabilities

This morning, the company announced it bolstered its own gene therapy activities with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company.

November 12, 2020
·
3 min read
·
Alex Keown
Business

Getting to Know Dr. James Garner, CEO of Kazia Therapeutics

BioSpace recently spoke with Dr. James Garner, CEO of Kazia Therapeutics, an oncology company that is focused on the development of cancer drugs.

November 12, 2020
·
5 min read
·
Gina Hagler
BioCapital

New Targeted Approach Could Prevent Toxicities Associated with Neurological Gene Therapies

Researchers from Penn Medicine have developed a new targeted approach that modifies viral vectors and inhibits toxicities in the sensory neurons of dorsal root ganglia that commonly occur following the use of gene therapy for neurological diseases.

November 12, 2020
·
2 min read
·
Brandon May
Business

BioSpace Movers & Shakers, November 13

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

November 12, 2020
·
7 min read
·
Alex Keown